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osting by EAbstract Acquired torsade de pointes ventricular tachycardia (TdP) is a rare but serious life-
threatening arrhythmia caused by an array of cardiac and non-cardiac drugs. It is often refractory
to pharmacological therapy and may result in death or require frequent deﬁbrillations. In our case
study a young female patient with no underlying heart disease developed very frequent sustained
TdP requiring frequent deﬁbrillations without which she would have certainly died. The ventricular
arrhythmia in this patient was of multifactorial origin – cisapride, drug–drug interaction and per-
sistent vomiting resulting in electrolyte disturbance and malnutrition. The patient survived after
more than 300 deﬁbrillation shocks over a period of 5 days and she is still alive 12 years later.
ª 2010 King Saud University. All rights reserved.1. Introduction
Polypharmacy is often unavoidable in patients with multiple
problems. However the treating physician must be aware of
the risks and be vigilant for complications especially ventricu-
lar arrhythmias which may be fatal. Every effort to avoid8916906.
com (S. Ghazal).
ity. All rights reserved. Peer-
d University.
lsevierdrug–drug interaction in a high risk patient should be made,
but if TdP occurs, proper persistent management may be effec-
tive and life saving. This brief report is about a young female
who developed refractory and frequent TdP as a result of vom-
iting and polypharmacy. She was successfully treated by cor-
recting her electrolyte disturbance and stopping the
offending drug which in our case was cisapride.
2. The case
This is a 36-year old lady who is Para 5 + 2, had Caesarean
section on October 24, 1998. Due to uncontrollable uterine
bleeding hysterectomy had to be done. She presented on
November 18, 1998 to ER complaining of abdominal pain,
fever, nausea and vomiting of 3 days duration. Physical exam-
ination showed heart rate: 106 bpm, BP: 120/70 mmHg, and
temperature: 37.9 C. A tender supra-pubic mass 10 · 10 cm
Figure 1 ECG tracing representing classical Torsades de pointes pattern at ventricular rate of approximately 210 beat per minute.
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Electrocardiogram showed sinus tachycardia with QTc (Bazett
formula) of 440 ms. Investigation showed Hgb 9.7 g/dl MCV
79, WBC 7.0 k/ll, serum albumin 3.1 g/dl K 3.9 meq/L cor-
rected Ca 7.9 mg/dl. Patient was admitted to OB/GYN service
with impression of infected rectus sheath hematoma. The pa-
tient was started on loperamide, metronidazole, nitrofurantoin
and later trimethoprim/sulfamethoxazole and tetracycline were
added after culture and sensitivity results. Patient continued to
have severe nausea vomiting and anorexia despite all trial of
anti-emetics including metoclopromide and ondansetron.
Upper GI endoscopy on December 1, 1998 revealed non-ulcer
dyspepsia and GERD. Ranitidine 150 mg po bid, and cisa-
pride 10 mg tid were added. Two days later on December 3,
1998, she collapsed and became unconscious and pulseless.
Found to have ventricular tachycardia (Fig. 1) which re-
sponded to deﬁbrillation. The patient was put on mechanical
ventilation and shifted to ICU. ECG showed prolonged QTc
measuring 630 ms. Serum K 3.2 meq/L, Mg 1.6 mg/dl which
were corrected by intravenous MgSO4 for a total dose 5 g
and KCl 40 meq/L at 100 cc/h during her stay in the ICU.
The patient continued to have frequent TdP requiring 50–70
deﬁbrillation shocks per day. Several anti-arrhythmic agents
including bretylium, phenytoin, isoprenaline, amiodarone,
lidocaine and MgSO4 were tried without any response. On
December 7 cisapride was discontinued as a possible cause of
this patient’s arrhythmia. The patient’s last episode of TdP oc-
curred on December 8, 1998. The vomiting also ceased. On
December 15 she was transferred to the female medical ward
and discharged the next day from the hospital. The patient
never came for cardiology follow up. Her hospital ﬁle showed
she was last seen in ER on September 30, 2008 for
gastroenteritis.
3. Discussion
Cisapride, a gastrointestinal prokinetic agent, is known to pro-
long the QT interval and lead to life-threatening TdP. In 1995
the ﬁrst case of ventricular arrhythmia linked to cisapride was
reported to the FDA (Janssen Pharmaceutica, 2000). By 1999,
the FDA received 117 report of patient developed QT prolon-
gation; 107, torsades de pointes; 16, polymorphic ventricular
tachycardia; 18, ventricular ﬁbrillation; 27, ventricular tachy-
cardia; 25, cardiac arrest; 16, serious (unspeciﬁed) arrhythmia;
and 15, sudden death; for a total of 341 individual patients af-
fected following use of cisapride of which 80 (23%) died
(Diane et al., 2001). By year 2000 cisapride was withdrawn
from the US market (Diane et al., 2001). Cisapride was further
studied and it was found to be associated with doubling to tri-
pling of the risk of hospitalization for ventricular arrhythmias
and eightfold risk in the initial prescription period (Hennessy
et al., 2008).Inhibitors of CYP3A4 like macrolides, midazolam, verapa-
mil, etc., may interfere with metabolism of cisapride and there-
fore, associated with increased risk of ventricular arrhythmias
(Gupta et al., 2007). Mechanism of drug induced QT prolon-
gation and TdP is explained by the fact that the myocardial
repolarization is primarily mediated by efﬂux of potassium
ions. Two subtypes of the delayed rectiﬁer K + current, Ikr
(rapid) and Iks (slow), are predominantly responsible for repo-
larization. Virtually all drugs that prolong QTc block Ikr
(Mitcheson et al., 2000).
A more recent study conducted on canine was able to dem-
onstrate the effect of cisapride on QT interval and induction of
TdP (Di Diego et al., 2003).
Recommended modalities of treatment in drug induced
TdP include intravenous magnesium sulfate as an initial ther-
apy of choice regardless of serum level (Banai and Tzivoni,
1993). If sustained hemodynamically unstable polymorphic
ventricular tachycardia or VF develops, immediate non-
synchronized deﬁbrillation is indicated. Serum potassium
should be maintained in the high-normal range (4.5–5 mmol/
L). Simultaneous use of other QT prolonging drugs must be
avoided; likewise medications likely to interfere with their
metabolism must be promptly discontinued. Overdrive trans-
venous pacing shortens QTc and is highly effective in prevent-
ing recurrence (Khan, 2002).
In our case TdP might not be solely due to drug induced
QT interval prolongation. Eating disorders including anorexia
nervosa, bulimia and binging and purging are known to cause
QT prolongation (Takimoto, 2004). Bulimia nervosa is a pri-
marily psychological disorder but the QT interval prolonga-
tion is mainly due to the metabolic derangements associated
with repeated vomiting. Hypokalemia, hypochloremia and
metabolic alkalosis were observed (Mitchell et al., 1983).
In our case we felt that cardiac effect of repeated vomiting
was a signiﬁcant contributory factor similar to what happens
in bulimia nervosa. It is safe to conclude that it was of multi-
factorial origin including cisapride, drug–drug interaction
which affected metabolism of cisapride by inhibition of
CYP3A4 (metronidazole, ranitidine, and amiodarone) and
electrolyte disturbances resulting from repeated vomiting and
poor nutritional intake.
Despite trial of many anti-arrhythmic agents she continued
having frequent episodes of sustained TdP requiring at times
more than 100 deﬁbrillation shocks in a day. The persistence
of the team paid of and the patient recovered and was dis-
charged in a good condition.
4. Conclusion
Drug induced torsade de pointes is a very serious arrhythmia
and physicians must be specially watchful for this complication
in high risk patients on certain drugs known to cause QTc pro-
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and polypharmacy are known risk factors for torsade de poin-
tes. The arrhythmia is life threatening and most drug related
fatalities are due to this proarrhythmic effect. These patients
should be managed aggressively paying special attention to
immediately stopping the culprit drug and magnesium admin-
istration and correcting all the risk factors.
It is very critical to identify the possible cause(s) of the
arrhythmia since elimination of the cause is essential. Persis-
tent vomiting might have cardiac complication similar to that
of bulimia nervosa, however, further studies are needed to
establish such association. We advice a careful approach for
patient on polypharmacy and metabolic disturbances. The fact
that after more than 300 deﬁbrillation shocks the patient is still
alive more than 12 years later, emphasizes that the treating
physician must be perseverant in managing drug induced tor-
sade de pointes since it is a potentially correctable arrhythmia.
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